A Phase IIa, single-arm, multi center study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with advanced squamous non-small-cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 27 Nov 2019 Planned End Date changed from 25 Jan 2021 to 24 Feb 2021.
- 09 Oct 2019 Planned number of patients changed from 45 to 40.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology